New research has found that providing psychosocial counseling and avoiding prescribed opioids or benzodiazepines are among the variables that can reduce mortality rates in opioid use disorders. Medication treatment did not affect death rates.
A Boston Medical Center study has found that just over one-quarter of adolescents and young adults diagnosed with an opioid use disorder from 2001-2014 received a prescription for buprenorphine or naltrexone.
The National Institute on Drug Abuse (NIDA) is funding a study that will determine whether direct observation of patients receiving buprenorphine treatment can improve retention in treatment and drug use outcomes.
Proove Biosciences, which markets technology designed to predict a patient's response to opioid dependence medications and other drugs, has had its office headquarters raided in an apparent healthcare fraud probe.